Lab
Prime Diagnostics Lab INC.
Prime Diagnostics Lab INC. was paid $143K by Medicaid between Jul 2024 and Dec 2024, across 8 billing codes. Its largest line is 87502, Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets — 27% of everything it billed.
33Billing provider infoPRIME DIAGNOSTICS LAB INC.
SOUTHFIELD, MI 48034
SOUTHFIELD, MI 48034
33aNPI1093351470assigned 11/20/2019
33bProvider typeClinical Medical Laboratory
28Total paid$143K
24GClaims3,419
24DCodes billed8
24AFirst – last monthJul 2024 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Michigan
Rank by total paid#71 of 108
Median peer was paid$588K
This provider vs. median0.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2024incomplete | 3,419 | $143K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 27% | 604 | 399 | $38K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 24% | 324 | 304 | $34K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 20% | 252 | 141 | $29K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 8.7% | 292 | 276 | $12K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 8.6% | 602 | 399 | $12K |
| 87400 | 7.8% | 1,199 | 399 | $11K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 3.6% | 45 | 38 | $5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 101 | 101 | $284.25 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHINA SHAKIL, SYEDA (CEO)